Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of “Strong Buy” by Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus price objective of $6.50 for the company and are predicting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned Capricor Therapeutics an industry rank of 160 out of 265 based on the ratings given to related companies.

A number of research firms have commented on CAPR. ValuEngine raised Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. HC Wainwright upped their price target on Capricor Therapeutics from $2.15 to $6.50 and gave the company a “buy” rating in a research report on Friday, September 15th.

Shares of Capricor Therapeutics (CAPR) opened at $1.58 on Friday. The firm has a market capitalization of $42.45, a PE ratio of -2.39 and a beta of -2.99. Capricor Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $4.25.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $1.00 million. The company’s revenue was down 58.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.29) earnings per share. analysts forecast that Capricor Therapeutics will post -0.7 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Virtu KCG Holdings LLC raised its position in Capricor Therapeutics by 571.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 152,614 shares during the last quarter. Wells Fargo & Company MN bought a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $107,000. Jane Street Group LLC bought a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $190,000. Finally, Belpointe Asset Management LLC bought a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $249,000. 3.87% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of “Strong Buy” by Brokerages” was reported by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://weekherald.com/2017/12/30/capricor-therapeutics-inc-capr-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply